12:00 AM
 | 
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bosutinib regulatory update

FDA accepted for review an NDA for Pfizer's bosutinib to treat previously treated Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >